102 related articles for article (PubMed ID: 2962589)
1. Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
Farthing CF; Dalgleish AG; Clark A; McClure M; Chanas A; Gazzard BG
AIDS; 1987 May; 1(1):21-5. PubMed ID: 2962589
[TBL] [Abstract][Full Text] [Related]
2. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
Gaub J; Pedersen C; Poulsen AG; Mathiesen LR; Ulrich K; Lindhardt BO; Faber V; Gerstoft J; Hofmann B; Lernestedt JO
AIDS; 1987 May; 1(1):27-33. PubMed ID: 2962590
[TBL] [Abstract][Full Text] [Related]
3. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
Jacobson MA; Crowe S; Levy J; Aweeka F; Gambertoglio J; McManus N; Mills J
J Infect Dis; 1988 Oct; 158(4):862-5. PubMed ID: 2844921
[No Abstract] [Full Text] [Related]
4. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
Ahlmén J; Wijnween AC; Brynger H; Lycke E
Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316
[TBL] [Abstract][Full Text] [Related]
5. Declining levels of HIV P24 antigen in serum during treatment with foscarnet.
Bergdahl S; Sönnerborg A; Larsson A; Strannegard O
Lancet; 1988 May; 1(8593):1052. PubMed ID: 2896890
[No Abstract] [Full Text] [Related]
6. A trial with ribavirin in patients with AIDS or AIDS-related complex.
Crocchiolo P; Pristera R; Lazzarin A; Chemotti M; Froldi M; Palazzini E; Verani P; Orecchia A; Moroni M
Boll Ist Sieroter Milan; 1989; 68(2):185-90. PubMed ID: 2491303
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
Ulbricht A; Färber I; Wutzler P
Acta Virol; 1985 Dec; 29(6):493-8. PubMed ID: 2869661
[TBL] [Abstract][Full Text] [Related]
8. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
9. A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet.
Seidel EA; Koenig S; Polis MA
AIDS; 1993 Jul; 7(7):941-5. PubMed ID: 8357555
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study.
Lawee D; Rosenthal D; Aoki FY; Portnoy J
CMAJ; 1988 Feb; 138(4):329-33. PubMed ID: 2962712
[TBL] [Abstract][Full Text] [Related]
11. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
[TBL] [Abstract][Full Text] [Related]
12. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.
Wainberg MA; Salomon H; Gu Z; Montaner JS; Cooley TP; McCaffrey R; Ruedy J; Hirst HM; Cammack N; Cameron J
AIDS; 1995 Apr; 9(4):351-7. PubMed ID: 7540846
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation.
Locke TJ; Odom NJ; Tapson JS; Freeman R; McGregor CG
J Heart Transplant; 1987; 6(2):120-2. PubMed ID: 3040944
[TBL] [Abstract][Full Text] [Related]
14. Therapy of human immunodeficiency virus infections.
Pomerantz RJ; Schooley RT
Clin Lab Med; 1987 Dec; 7(4):793-813. PubMed ID: 2446817
[TBL] [Abstract][Full Text] [Related]
15. Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study.
Eeftinck Schattenkerk JK; Danner SA; Lange JM; Paul DA; van Boxtel CJ; Miedema F; Schellekens PT; Goudsmit J
Arch Intern Med; 1988 Jan; 148(1):209-11. PubMed ID: 2447847
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.
Straw JA; Loo TL; de Vera CC; Nelson PD; Tompkins WA; Bai SA
J Acquir Immune Defic Syndr (1988); 1992; 5(9):936-42. PubMed ID: 1387417
[TBL] [Abstract][Full Text] [Related]
17. Enrichment of early HSV-induced proteins in phosphonoformate-treated cells.
Lehtinen MO; Lehtinen TK; Leinikki PO
Acta Virol; 1984 Jan; 28(1):11-8. PubMed ID: 6143492
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate).
Weber JN; Thom S; Barrison I; Unwin R; Forster S; Jeffries DJ; Boylston A; Pinching AJ
Gut; 1987 Apr; 28(4):482-7. PubMed ID: 3034745
[TBL] [Abstract][Full Text] [Related]
19. Isolation of HTLV III/LAV from drug addicts in Palermo.
Romano N; Portera M; Vitale F; Russo Alesi D; Torregrossa MV; Perrera G
Microbiologica; 1987 Jan; 10(1):73-80. PubMed ID: 3646455
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.
Sandstrom EG; Kaplan JC; Byington RE; Hirsch MS
Lancet; 1985 Jun; 1(8444):1480-2. PubMed ID: 2409414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
